DO NOT ENTER: /V.B.G./

## Amendments to the Claims

Listing of Claims:

1. (Withdrawn) A compound of formula I:

## Z'-CO-A-B-NH-Z (I)

wherein:

Z is H or an amino protecting group;

Z' is OH, a protected or activated hydroxyl group or Cl;

A is an optionally substituted C5-6 arylene group;

B is an optionally substituted C<sub>5-6</sub> arylene group;

except for the following compounds:

(Withdrawn-previously presented) The compound according to claim 1, wherein when B is phenylene with an –NH- β to the bond between A and B, then -A-CO- is not:

$$\stackrel{\mathsf{N}}{\prec} \stackrel{\mathsf{Me}}{\downarrow} \qquad \stackrel{\mathsf{N}}{\leftarrow} \qquad \stackrel{\mathsf{N}}{\prec} \stackrel{\mathsf{N}}{\downarrow} \qquad \stackrel{\mathsf{N}}{\prec} \stackrel{\mathsf{N}}{\downarrow} \qquad \stackrel{\mathsf{N}}{\prec} \stackrel{\mathsf{N}}{\downarrow} \stackrel{\mathsf{N}}{\downarrow} \qquad \stackrel{\mathsf{N}}{\prec} \stackrel{\mathsf{N}}{\downarrow} \stackrel{\mathsf{N}}{\downarrow} \qquad \stackrel{\mathsf{N}}{\prec} \stackrel{\mathsf{N}}{\downarrow} \stackrel{\mathsf{N}}$$

 (Withdrawn-previously presented) The compound according to claim 1, wherein when – NH-B- is:

then -A-CO- is not:

- (Withdrawn previously presented) The compound according to claim 1, wherein Z' is a
  protected hydroxyl group.
- (Withdrawn –previously presented) The compound according to claim 1, wherein A and B are independently selected from phenylene, and arylene groups derived from C₅ heteroaryl groups having one or two heteroatoms.
- 6. (Previously presented) A polyamido moiety comprising at least one unit of formula II:

wherein:

A is an optionally substitu+ted C5-6 arylene group;

B is an optionally substituted C<sub>5-6</sub> arylene group;

wherein said unit of formula II is bound to one or more other units selected from:

- (i) units of formula II: and
- (ii) amino-heteroarylene-carbonyl units of formula III:

wherein E is either optionally substituted C<sub>5-20</sub> heteroarylene or C<sub>8-10</sub> heteroarylene-C<sub>5-20</sub> arylene.

- 7. (Canceled)
- 8. (Previously presented) The polyamido moiety according to claim 6, wherein A and B are independently selected from phenylene, and heteroarylene groups derived from  $C_5$  heteroaryl groups having one or two heteroatoms.

- (Canceled).
- 10. (Withdrawn previously presented) The compound according to claim 9, having a formula IV:

$$Z''-(T)_n-CO-(CH_2)_q-NR^1R^2$$
 (IV)

wherein:

Z" is OH or a protected hydroxy group;

each T is independently selected from units of formulae II, III or V:

wherein:

a' is from 1 to 3:

n is from 1 to 10:

q is from 1 to 3; and

R1 and R2 are independently selected from C14 alkyl.

11. (Withdrawn – previously presented) The compound according to claim 9, comprising a pyrrolobenzodiazepine moiety of formula VI:

$$-Y-X-Q \xrightarrow{R^0} \overset{R^{10}}{\underset{R^0}{\bigvee}} \overset{R^{11}}{\underset{R^0}{\bigvee}}$$
  $(VI)$ 

and salts, solvates, chemically protected forms, and prodrugs thereof, wherein:

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

 $R^2$  and  $R^3$  are independently selected from –H, -OH, =O, =CH<sub>2</sub>, -CN, -R, OR, halo, =CH-R, O-SO<sub>2</sub>-R, CO<sub>2</sub>R and COR;

R<sup>6</sup>, R<sup>7</sup> and R<sup>9</sup> are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me<sub>8</sub>Sn and halo; where R and R' are independently selected from optionally substituted C<sub>1-7</sub> alkyl, C<sub>3-20</sub> heterocyclyl and C<sub>5-20</sub> aryl groups;

Response to Office Action of 1.19.10 U.S. Patent Application No. 10/591,140

or R<sup>6</sup> and R<sup>7</sup> together form a group -O-(CH<sub>2</sub>)<sub>p</sub>-O-, where p is 1 or 2;

 $R^{10}$  is a nitrogen protecting group and  $R^{11}$  is either O- $R^{15}$ , wherein  $R^{15}$  is a hydroxyl protecting group. or  $R^{15}$  is OH; or

R<sup>10</sup> and R<sup>11</sup> together form a double bond between N10 and C11;

Q is selected from O, S, NH or a single bond;

X is a divalent group such that HY = R, or a single bond;

Y is either NH or C(=O).

- (Withdrawn previously presented) The compound according to claim 11, wherein R<sup>9</sup> is
- 13. (Withdrawn previously presented) The compound according to claim 11, wherein R<sup>6</sup> is selected from H, OH, OR, SH, NH<sub>2</sub>, nitro and halo.
- (Withdrawn previously presented) The compound according to claim 11, wherein R<sup>7</sup> is independently selected from H, OR, SH, SR, NH<sub>2</sub>, NHR, NRR' and halo.
- (Withdrawn previously presented) The compound according to claim 11, wherein R<sup>10</sup> is BOC. Troc or alloc.
- (Withdrawn previously presented) The compound according to claim 11, wherein R<sup>15</sup> is THP or a silvl oxygen protecting group.
- (Withdrawn previously presented) The compound according to claim 11, wherein R<sup>10</sup> and R<sup>11</sup> together form a double bond between N10 and C11.
- (Withdrawn previously presented) The compound according to claim 11, wherein Q is
   NH. O or a single bond.
- 19. (Withdrawn previously presented) The compound according to claim 11, wherein X is a single bond or  $C_{1,7}$  alkylene.
- 20. (Withdrawn previously presented) The compound according to claim 11, wherein  ${\sf R}^3$  is H.

Response to Office Action of 1.19.10 U.S. Patent Application No. 10/591,140

- 21. (Withdrawn previously presented) The compound according to claim 11, wherein  ${\sf R}^2$  is  ${\sf R}$ .
- 22. (Canceled)
- (Previously presented) A pharmaceutical composition containing the compound of claim
   and a pharmaceutically acceptable carrier or diluent.
- 24. (Canceled)
- 25. (Withdrawn previously presented) A method of treatment of a proliferative disease, comprising administering to a subject in need of treatment a therapeutically-effective amount of the compound of claim 9.
- 26. (Canceled)